[{"data":1,"prerenderedAt":318},["ShallowReactive",2],{"story-1638-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":54,"questions":55,"relatedArticles":65,"body_color":316,"card_color":317},"1638",null,"Eli Lilly's Retatrutide: A Breakthrough in Obesity Treatment Reshaping Healthcare Economics","- Transformative Drug Signals Massive Shift in Weight Management and Pharmaceutical Innovation",[],[10,11,12,13,14,15,11,16,17,18,19,20,21,22,23,24,25,26,27,28,29,11,30,27,31,32,33,34,35,36,37,38,39,40,18,41,42,43,44,45,13,46,47,48,49,18,50,51,52,53],"https://cdn.benzinga.com/files/images/story/2025/12/11/New-Trump-Visa-Rules-May-Bar-Overweight-.jpeg?width=1200&height=800&fit=crop","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iQkwzcu1c6d8/v0/-1x-1.webp","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1RvqC7.img?w=768&h=402&m=6","https://www.nysun.com/_next/image?url=https%3A%2F%2Fwp.nysun.com%2Fwp-content%2Fuploads%2F2025%2F12%2FEli-Lilly-Getty.jpg&w=1200&q=75","https://investingnews.com/media-library/image.jpg?id=62307173&width=400","https://www.red94.net/news/wp-content/uploads/2025/12/74071-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l.jpg.png","https://www.statnews.com/wp-content/uploads/2025/04/GettyImages-2092480827-645x645.jpg","https://static.gurufocus.com/cdn-cgi/image/width=500,quality=100/logos/0C000007E3.png?20","https://static01.nyt.com/images/2025/12/11/multimedia/11HS-obesity-arthritis-wcqj/11HS-obesity-arthritis-wcqj-articleLarge.jpg?quality=75&auto=webp&disable=upscale","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iIv4fPUqTRks/v3/640x360.jpg","https://cdn.sanity.io/images/0vv8moc6/pharmexec/d2f41521072903a34f6561de83b736e3ee62f09b-1280x720.png?w=1280&max-h=720&fit=crop&auto=format","https://media.assettype.com/bloombergquint/2025-12-11/30ylnb80/445803805.jpg?w=1200&auto=format%2Ccompress&q=60&rect=0%2C0%2C3500%2C1969&","https://cdn.sanity.io/images/0vv8moc6/patientcare/8c11ab0c86f38a8d15b665ce7284994288aaf1c8-863x572.jpg","https://images.ft.com/v3/image/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2Ff5b4ec07-18a9-4bd4-a5cd-a629f1382b2a.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1","https://static.independent.co.uk/2025/08/28/9/32/SEI263485531.jpeg?width=1200&height=630&fit=crop","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291269124/image_1291269124.jpg?io=getty-c-w630","https://images.mktw.net/im-39352247?width=1260&height=783","https://images.barrons.com/im-39666261?width=639&height=426","https://imgproxy.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/18819797/n1jtna/ALTERNATES/master-3_2/eli-lilly","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189405678/image_2189405678.jpg?io=getty-c-w630","https://static.independent.co.uk/2025/12/11/15/41/GettyImages-2092477287.jpeg","https://i-invdn-com.investing.com/trkd-images/LYNXMPELBA0NV_L.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg?io=getty-c-w1280","https://www.reuters.com/resizer/v2/F4XDD7YGTRJGRGRAWHHQZ7PCM4.jpg?auth=e5028ddf4c843ac2f08f68908ea24176f8537ef9f980d8d740135d0afa8fd642&width=1920&quality=80","https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg","https://pharmaphorum.com/sites/default/files/styles/x_large/public/2024-12/Lilly_Manufacturing_1200x675.jpg?itok=Cs-q89wb","https://imgproxy.divecdn.com/I4t7D87UBz8mH7--jgiFZv86QeViOR_jNjzyf5HBjTg/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDE0NDc0NzEzLmpwZw==.webp","https://media-cldnry.s-nbcnews.com/image/upload/t_fit-1500w,f_auto,q_auto:best/mpx/2704722219/2025_12/1765466516996_tdy_news_8a_new_weight_loss_drug_251211_1920x1080-j93qjv.jpg","https://www.investors.com/wp-content/uploads/2017/11/Stock-biotech-10-shutter.jpg","https://img.businessoffashion.com/resizer/v2/GRXB7K7PLVCJDOI3ZLMUWY6VZQ.png?auth=c8ff978eb276e0d4e6f63f39f072a5dcc138b7be9e9b9cb3c4423f23ee64cb10&width=1440","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1318526353/image_1318526353.jpg?io=getty-c-w1280","https://www.irishtimes.com/resizer/v2/QWESI6CARNDSBJQJAXWUIPJTNU.jpg?auth=d7f65ab22880864dafd1c15bc623751e2d02317ad2137d4b4939d1485699fbed&smart=true&width=1600&height=1600","https://news-assets.stockstory.org/cover-images/_1400x700_crop_center-center_none/eli-lilly-cover-image-3d82148895e3_2025-02-04-094122_uhvj.jpeg","https://cdn.sanity.io/images/0vv8moc6/hcplive/99bc9deb311605e929d2399ee964420e8910177c-1200x630.png","https://media.consumeraffairs.com/files/cache/news/weight-loss2_qWAToDe_large.webp","https://marketminute.ghost.io/content/images/size/w1200/2025/12/3e6956ec-adc9-4bbe-a0d3-0f11d3d1642f.png","https://static.biospace.com/dims4/default/5501710/2147483647/strip/true/crop/2121x1194+0+110/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2Fc0%2Fea%2F0255e0d84c909481d4c844bad1cd%2Fistock-2228635589.jpg","https://static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/scientist-laboratory-drugs-getty.jpg","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1c7ry3.img?w=1536&h=1024&m=4&q=42","https://www.geneonline.com/wp-content/uploads/EN_Mobile_Dec_HIV_AIDS-450x350.png","https://medcitynews.com/wp-content/uploads/sites/7/2024/12/GettyImages-sb10068935i-001.jpg","https://image.cnbcfm.com/api/v1/image/108230176-1764603822722-108230176-17637559702025-11-21t201158z_1546648356_rc261iafo6zz_rtrmadp_0_lilly-stocks.jpg?v=1764603832&w=1600&h=900","https://images.wsj.net/im-03838950?width=700&height=466","The pharmaceutical landscape is witnessing a revolutionary moment with **Eli Lilly's retatrutide**, a groundbreaking obesity drug that promises to redefine medical approaches to weight management and metabolic health. By achieving an unprecedented average weight loss of 28.7% in clinical trials, this medication represents far more than a traditional pharmaceutical intervention—it's a potential paradigm shift in how we conceptualize obesity treatment.\n\nWhat distinguishes retatrutide is its sophisticated **triple-hormone mechanism**, simultaneously targeting GLP-1, GIP, and glucagon. This innovative approach transcends existing single or dual-hormone treatments, delivering more potent appetite control and metabolic regulation. The drug's clinical performance is nothing short of remarkable: not only did participants lose substantial weight, but they also experienced significant knee pain reduction, suggesting broader therapeutic potential beyond weight management.\n\nThe market implications are profound. **Eli Lilly** is positioning itself as a dominant player in the rapidly evolving obesity pharmaceutical sector, directly challenging competitors like Novo Nordisk. With 23.7% of high-dose trial participants losing at least 35% of their body weight, retatrutide could potentially disrupt multiple healthcare markets—from weight loss medications to pain management treatments.\n\nHowever, the path isn't without challenges. Approximately 18% of patients discontinued treatment due to side effects like nausea and diarrhea, indicating that while revolutionary, the drug isn't a universal solution. Medical experts like Dr. Caroline Apovian nonetheless praise its potential, comparing its weight loss benefits to surgical interventions.\n\nThe broader significance extends beyond individual treatment. Retatrutide signals a transformative approach to obesity—viewing it not just as a cosmetic concern, but as a complex metabolic condition requiring sophisticated, multi-dimensional pharmaceutical interventions. By addressing weight loss and associated pain simultaneously, Eli Lilly is reimagining the entire therapeutic landscape.\n\nStrategic implications are clear: pharmaceutical companies must now invest in multi-mechanism treatments that offer comprehensive health solutions. For healthcare providers, investors, and patients, retatrutide represents more than a drug—it's a glimpse into a future of more holistic, precise medical treatments.",[56,59,62],{"title":57,"answer":58,"author":5,"avatar":5,"time":5},"What challenges does retatrutide face in widespread adoption?","The primary challenges include side effects like nausea (43%), diarrhea (33%), and vomiting (20.9%), which led to 18% of high-dose trial participants discontinuing treatment. Additionally, the drug will require extensive regulatory approval and long-term safety studies before widespread medical adoption.",{"title":60,"answer":61,"author":5,"avatar":5,"time":5},"How does retatrutide differ from existing obesity treatments?","Retatrutide uniquely targets three hormones (GLP-1, GIP, and glucagon) simultaneously, compared to existing treatments that typically target only one or two. This multi-hormone approach enables more comprehensive metabolic regulation, resulting in significantly higher weight loss percentages—up to 28.7% in clinical trials.",{"title":63,"answer":64,"author":5,"avatar":5,"time":5},"What are the potential market implications of this drug?","Eli Lilly is positioning itself to disrupt multiple healthcare markets, including weight loss medications, pain management, and metabolic health treatments. The drug's ability to deliver substantial weight loss while reducing knee pain suggests potential for broad medical applications and significant market expansion.",[66,71,75,79,83,87,91,95,99,103,107,111,115,119,123,127,131,135,139,142,146,150,154,158,162,166,170,174,178,182,186,190,193,197,201,204,208,212,216,220,224,228,232,236,240,244,247,251,254,258,262,265,269,273,277,281,285,289,293,296,300,304,308,312],{"id":67,"title":68,"source":69,"logo":14,"time":70},68511,"Zepbound Maker Eli Lilly Reports Patients Achieved Dramatic Weight Loss in Study of Newest Obesity Drug","https://www.nysun.com/article/zepbound-maker-eli-lilly-reports-patients-achieved-dramatic-weight-loss-in-study-of-newest-obesity-drug","2D AGO",{"id":72,"title":73,"source":74,"logo":37,"time":70},69688,"Lilly’s three-pronged drug puts obesity field ‘on notice’","https://www.biopharmadive.com/news/lilly-retatrutide-obesity-osteoarthritis-pain-study-results/807641/",{"id":76,"title":77,"source":78,"logo":5,"time":70},68510,"Eli Lilly reports positive Phase 3 trial results for obesity drug retatrutide","https://www.proactiveinvestors.com/companies/news/1084262/eli-lilly-reports-positive-phase-3-trial-results-for-obesity-drug-retatrutide-1084262.html",{"id":80,"title":81,"source":82,"logo":21,"time":70},69687,"Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial","https://www.pharmexec.com/view/lilly-retatrutide-positive-topline-results-successful-phase-iii-trial",{"id":84,"title":85,"source":86,"logo":28,"time":70},69686,"Eli Lilly’s Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.","https://www.barrons.com/articles/eli-lilly-stock-obesity-weight-loss-drug-1bd03050?gaa_at=eafs&gaa_n=AWEtsqcuiOqPrt6d4PlP5-nUL1GxCj2Qxm4BKkl9mog1B4Et5uiJTUHpAapT&gaa_ts=693b278c&gaa_sig=hbLySupm9UiFV7Gagl-JujeR5p4ZVeEx9kTdcHZHs_j1uPXj90R6hMBW5eKM9lnQGQL7Tm9SaT_rg0xryypycA%3D%3D",{"id":88,"title":89,"source":90,"logo":48,"time":70},69685,"Major weight loss, pain relief seen with Eli Lilly's next-gen drug in late-stage trial","https://www.foxbusiness.com/lifestyle/major-weight-loss-pain-relief-seen-eli-lillys-next-gen-drug-late-stage-trial",{"id":92,"title":93,"source":94,"logo":18,"time":70},68515,"Eli Lilly's (LLY) New Weight Loss Drug Shows Promising Results i","https://www.gurufocus.com/news/3245227/eli-lillys-lly-new-weight-loss-drug-shows-promising-results-in-clinical-trials",{"id":96,"title":97,"source":98,"logo":45,"time":70},68514,"Lilly reports promising results from its weight-loss drug trial","https://www.consumeraffairs.com/news/lilly-reports-promising-results-from-its-weight-loss-drug-trial-121125.html",{"id":100,"title":101,"source":102,"logo":18,"time":70},68513,"Eli Lilly (LLY) Shows Competitive Efficacy in Initial Obesity St","https://www.gurufocus.com/news/3245217/eli-lilly-lly-shows-competitive-efficacy-in-initial-obesity-study",{"id":104,"title":105,"source":106,"logo":12,"time":70},68512,"Lilly’s Experimental Shot Cuts Body Weight by 23% in Study","https://www.bloomberg.com/news/articles/2025-12-11/lilly-s-experimental-shot-reduces-body-weight-by-23-in-study",{"id":108,"title":109,"source":110,"logo":30,"time":70},69689,"Eli Lilly: Retatrutide Justifies Hype With Best Weight Loss Data Yet - I'm Sold (NYSE:LLY)","https://seekingalpha.com/article/4852537-eli-lilly-retatrutide-justifies-hype-with-best-weight-loss-data-yet-im-sold",{"id":112,"title":113,"source":114,"logo":47,"time":70},68519,"Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges","https://www.biospace.com/drug-development/lillys-retatrutide-scores-triple-trial-triumph-with-26-weight-loss-but-new-safety-signal-emerges",{"id":116,"title":117,"source":118,"logo":5,"time":70},68518,"Eli Lilly Reports Strong Late-Stage Results for Next-Generation Obesity Drug Retatrutide","https://finance.yahoo.com/news/eli-lilly-reports-strong-stage-142608772.html",{"id":120,"title":121,"source":122,"logo":35,"time":70},68517,"Pharmalittle: We're reading about Lilly's new obesity drug, E.U. pharma rules, and much more","https://www.statnews.com/pharmalot/2025/12/11/lilly-obesity-weight-ftc-teva-patents-europe-testosterone/",{"id":124,"title":125,"source":126,"logo":10,"time":70},68516,"Eli Lilly's Next-Gen Experimental Drug Cuts Body Weight By 29%, Helps In Knee Pain","https://www.benzinga.com/news/health-care/25/12/49333989/eli-lillys-next-gen-experimental-drug-cuts-body-weight-by-29-helps-in-knee-pain",{"id":128,"title":129,"source":130,"logo":31,"time":70},69680,"A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds","https://www.the-independent.com/news/health/eli-lilly-weight-loss-drug-b2882666.html",{"id":132,"title":133,"source":134,"logo":13,"time":70},69684,"Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial","https://www.msn.com/en-us/health/other/eli-lilly-s-next-generation-obesity-drug-delivers-strong-weight-loss-reduces-knee-pain-in-late-stage-trial/ar-AA1S9a94?cvid=693af2dddd174f74a6680543d7c98933&ocid=U452DHP",{"id":136,"title":137,"source":138,"logo":41,"time":70},69683,"Lilly stock rises on data for new weight loss drug (LLY:NYSE)","https://seekingalpha.com/news/4530594-lilly-stock-rises-data-new-weight-loss-drug",{"id":140,"title":133,"source":141,"logo":13,"time":70},69682,"https://www.msn.com/en-us/health/other/eli-lilly-s-next-generation-obesity-drug-delivers-strong-weight-loss-reduces-knee-pain-in-late-stage-trial/ar-AA1S9a94?cvid=693af5b4e5584b0684fd9ebabd154851&ocid=nl_article_link",{"id":143,"title":144,"source":145,"logo":42,"time":70},69681,"Eli Lilly’s latest shot helped patients lose 29% of body weight in trials","https://www.irishtimes.com/business/2025/12/11/eli-lilly-shot-helped-patients-lose-29-of-body-weight/",{"id":147,"title":148,"source":149,"logo":27,"time":70},68489,"Eli Lilly’s newest weight-loss drug relieved pain in patients with knee osteoarthritis","https://www.marketwatch.com/story/eli-lillys-newest-weight-loss-drug-relieved-pain-in-patients-with-knee-osteoarthritis-b7a6bcd2?gaa_at=eafs&gaa_n=AWEtsqcyAE9nAK_5i8k67mrwr0OWwZvKamjHS6c7-faP1YGZTX6un7IUREXq&gaa_ts=693aef43&gaa_sig=iFgmFHapx5CvnEUIYxRwox6AqGGVxHpKZ6yWWQTfu4MNTKDplBJsOzRhlXAWPnSsSiZ3fE8uV7kOOQZhOU4DMQ%3D%3D",{"id":151,"title":152,"source":153,"logo":34,"time":70},68522,"Lilly's next-gen drug tops Zepbound on weight loss in late-stage trial","https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-next-gen-drug-tops-zepbound-weight-loss-late-stage-osteoarthritis-trial-2025-12-11/",{"id":155,"title":156,"source":157,"logo":36,"time":70},68521,"Lilly's obesity triple pulls off 29% weight loss in trial","https://pharmaphorum.com/news/lillys-obesity-triple-pulls-29-weight-loss-trial",{"id":159,"title":160,"source":161,"logo":5,"time":70},68520,"Lilly's 'triple-G' drug leads to 28.7% weight loss in first pivotal test","https://firstwordpharma.com/story/6739121",{"id":163,"title":164,"source":165,"logo":29,"time":70},68524,"Eli Lilly delivers positive data from next-generation obesity drug","https://medwatch.com/News/Pharma___Biotech/article18834041.ece",{"id":167,"title":168,"source":169,"logo":5,"time":70},68523,"Lilly Reports Positive Results in Next-Gen Obesity Drug Trial","https://finance.yahoo.com/news/eli-lilly-reports-positive-results-125400633.html",{"id":171,"title":172,"source":173,"logo":11,"time":70},69690,"Novo rises as Eli Lily drug's efficacy soothes concerns over CagriSema","https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3XH1DL:0-novo-rises-as-eli-lily-drug-s-efficacy-soothes-concerns-over-cagrisema/",{"id":175,"title":176,"source":177,"logo":11,"time":70},68499,"Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial","https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3XH0TQ:0-lilly-s-next-gen-drug-tops-zepbound-on-weight-loss-in-late-stage-osteoarthritis-trial/",{"id":179,"title":180,"source":181,"logo":5,"time":70},68498,"Lilly’s retatrutide shows significant weight loss and pain relief in knee osteoarthritis trial By Investing.com","https://za.investing.com/news/company-news/lillys-retatrutide-shows-significant-weight-loss-and-pain-relief-in-knee-osteoarthritis-trial-93CH-4023772",{"id":183,"title":184,"source":185,"logo":24,"time":70},68497,"Eli Lilly shot helped patients lose 29% of body weight","https://www.ft.com/content/51b70635-0fc5-4dd2-b698-14c939f98d93",{"id":187,"title":188,"source":189,"logo":5,"time":70},69669,"Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial","https://finance.yahoo.com/news/lillys-triple-agonist-retatrutide-delivered-114500351.html",{"id":191,"title":148,"source":192,"logo":27,"time":70},69668,"https://www.marketwatch.com/story/eli-lillys-newest-weight-loss-drug-relieved-pain-in-patients-with-knee-osteoarthritis-b7a6bcd2?gaa_at=eafs&gaa_n=AWEtsqcD_dldyvxIMw5lYDYKnk1measJVXY9gvDXi3KxTOK486oZC1CH-p3y&gaa_ts=693b278c&gaa_sig=kHnjKF2i7LYCpqgi3151n6lfnNL6mRge57vxzmgry7eb8Ym5s8qvPpeJ56JA-gYdS6O-xrcCDJ4WriKx_oDsDA%3D%3D",{"id":194,"title":195,"source":196,"logo":5,"time":70},69704,"Lilly’s experimental shot cuts body weight by 23% in study","https://www.detroitnews.com/story/business/2025/12/11/lillys-experimental-shot-cuts-body-weight-by-23-in-study/87715472007/",{"id":198,"title":199,"source":200,"logo":44,"time":70},68492,"TRIUMPH-4: Retatrutide Delivers Weight Loss, Knee Osteoarthritis Pain Relief","https://www.hcplive.com/view/triumph-4-retatrutide-delivers-weight-loss-knee-osteoarthritis-pain-relief",{"id":202,"title":188,"source":203,"logo":15,"time":70},68491,"https://investingnews.com/lilly-s-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial/",{"id":205,"title":206,"source":207,"logo":18,"time":70},68490,"Eli Lilly (LLY) Reveals Promising Results from TRIUMPH-4 Study o","https://www.gurufocus.com/news/3244727/eli-lilly-lly-reveals-promising-results-from-triumph4-study-on-retatrutide",{"id":209,"title":210,"source":211,"logo":22,"time":70},68496,"Lillys Experimental Shot Cuts Body Weight By 23% In Study","https://www.ndtvprofit.com/business/obesity-market-weight-loss-lillys-experimental-shot-cuts-body-weight-by-23-per-cent-in-study",{"id":213,"title":214,"source":215,"logo":5,"time":70},68495,"Eli Lilly reports TRIUMPH-4 trial of retatrutide met primary endpoint","https://www.tipranks.com/news/the-fly/eli-lilly-reports-triumph-4-trial-of-retatrutide-met-primary-endpoint-thefly",{"id":217,"title":218,"source":219,"logo":16,"time":70},68494,"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial","https://www.red94.net/news/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l/",{"id":221,"title":222,"source":223,"logo":40,"time":70},68493,"Lilly’s Experimental Shot Reduces Body Weight by 23%","https://www.businessoffashion.com/news/beauty/eli-lilly-potent-weight-loss-shot/",{"id":225,"title":226,"source":227,"logo":26,"time":70},68500,"Lilly posts late-stage trial win for next-gen weight loss drug","https://seekingalpha.com/news/4530429-lilly-posts-late-stage-trial-win-next-gen-weight-loss-drug",{"id":229,"title":230,"source":231,"logo":19,"time":70},68544,"Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug","https://www.nytimes.com/2025/12/11/health/eli-lilly-retatrutide-weight-loss-drug.html",{"id":233,"title":234,"source":235,"logo":50,"time":70},69677,"Eli Lilly Obesity Drug Shows Weight Loss and Reduced Knee Pain in Late-Stage Trials","https://www.geneonline.com/eli-lilly-obesity-drug-shows-weight-loss-and-reduced-knee-pain-in-late-stage-trials/",{"id":237,"title":238,"source":239,"logo":53,"time":70},68543,"Eli Lilly Reports Dramatic Weight Loss in Next-Gen Obesity-Drug Trial","https://www.wsj.com/health/pharma/eli-lilly-reports-positive-results-from-study-of-weight-loss-drug-c4cc3af7?gaa_at=eafs&gaa_n=AWEtsqe3Plf8c-MC_kram7ZgFTX8iOam_ke0H3RKPPtu5JJBwX5jLiVEE0NO&gaa_ts=693aef43&gaa_sig=RSad3nqkzcTtm99IHBFiOy5z2U06vI48_vlM0PVnxZrbyMugT0RKkxmSbJX-0wUCdGsP6BYZ9r1IEuIXB1pBqw%3D%3D",{"id":241,"title":242,"source":243,"logo":25,"time":70},69676,"Next-generation obesity drug delivers promising results","https://www.independent.co.uk/bulletin/news/weight-loss-drug-retatrutide-eli-lilly-b2882847.html",{"id":245,"title":133,"source":246,"logo":52,"time":70},68542,"https://www.cnbc.com/2025/12/11/eli-lillys-weight-loss-drug-retatrutide-clears-first-late-stage-study.html",{"id":248,"title":249,"source":250,"logo":20,"time":70},69675,"Watch Lilly’s Experimental Shot Cuts Body Weight by 23% in Study","https://www.bloomberg.com/news/videos/2025-12-11/new-lilly-shot-cuts-body-weight-by-23-in-study-video",{"id":252,"title":176,"source":253,"logo":5,"time":70},68541,"https://finance.yahoo.com/news/lillys-next-gen-drug-tops-115557677.html",{"id":255,"title":256,"source":257,"logo":33,"time":70},69674,"Market Voices: Lilly's new obesity drug, Bessent, EQT's robotics move","https://seekingalpha.com/news/4530625-market-voices-lillys-new-obesity-drug-bessent-eqts-robotics-move",{"id":259,"title":260,"source":261,"logo":17,"time":70},68504,"Lilly’s next-gen obesity drug delivers major weight loss in Phase 3 trial, but with many discontinuations","https://www.statnews.com/2025/12/11/eli-lilly-retatrutide-weight-loss-obesity-tolerability-trial-results/",{"id":263,"title":188,"source":264,"logo":5,"time":70},68503,"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average",{"id":266,"title":267,"source":268,"logo":11,"time":70},68502,"Lilly climbs after obesity drug reduces weight by 28.7% in late-stage osteoarthritis trial","https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3XH0SA:0-lilly-climbs-after-obesity-drug-reduces-weight-by-28-7-in-late-stage-osteoarthritis-trial/",{"id":270,"title":271,"source":272,"logo":43,"time":70},69679,"Eli Lilly (LLY) Stock Is Up, What You Need To Know","https://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/36577151/eli-lilly-lly-stock-is-up-what-you-need-to-know/",{"id":274,"title":275,"source":276,"logo":5,"time":70},68501,"Eli Lilly stock climbs after retatrutide delivers massive weight loss in trial","https://uk.investing.com/news/stock-market-news/eli-lilly-stock-climbs-after-retatrutide-delivers-massive-weight-loss-in-trial-4412798",{"id":278,"title":279,"source":280,"logo":5,"time":70},69678,"Eli Lilly’s Weight Loss Superdrug Worked So Well During Trials, Some Quit Over Losing Too Much","https://gizmodo.com/eli-lillys-weight-loss-superdrug-worked-so-well-during-trials-some-quit-over-losing-too-much-2000698424",{"id":282,"title":283,"source":284,"logo":32,"time":70},68508,"Lilly’s next-gen drug shows greater weight loss than Zepbound in late-stage trial By Reuters","https://www.investing.com/news/stock-market-news/lillys-nextgen-drug-tops-zepbound-on-weight-loss-in-latestage-osteoarthritis-trial-4403032",{"id":286,"title":287,"source":288,"logo":38,"time":70},68507,"New Eli Lilly Weight Loss Drug Burns Fat, Reduces Knee Pain","https://www.today.com/video/new-eli-lilly-weight-loss-drug-burns-fat-reduces-knee-pain-254220869509",{"id":290,"title":291,"source":292,"logo":39,"time":70},68506,"Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss","https://www.investors.com/news/technology/eli-lillys-experimental-obesity-drug-cut-weight-by-23-7/",{"id":294,"title":176,"source":295,"logo":5,"time":70},68505,"https://www.marketscreener.com/news/lilly-s-next-gen-drug-tops-zepbound-on-weight-loss-in-late-stage-osteoarthritis-trial-ce7d50dbd988f420",{"id":297,"title":298,"source":299,"logo":46,"time":70},68509,"Eli Lilly's Retatrutide Soars: Unprecedented Trial Results Propel Pharma Giant, Ignite Obesity Market","https://markets.financialcontent.com/wral/article/marketminute-2025-12-11-eli-lillys-retatrutide-soars-unprecedented-trial-results-propel-pharma-giant-ignite-obesity-market",{"id":301,"title":302,"source":303,"logo":51,"time":70},69673,"Eli Lilly Drug for 3 Obesity Targets Sets New High Bar for Weight Loss in a Clinical Trial","https://medcitynews.com/2025/12/eli-lilly-retatrutide-glp1-gip-glucagon-obesity-weight-loss-osteoarthritis-lly/",{"id":305,"title":306,"source":307,"logo":23,"time":70},69672,"Retatrutide Achieves Up to 28.7% Weight Loss and Marked Knee Pain Reduction in Phase 3 TRIUMPH-4 Trial","https://www.patientcareonline.com/view/retatrutide-achieves-up-to-28-7-weight-loss-and-marked-knee-pain-reduction-in-phase-3-triumph-4-trial",{"id":309,"title":310,"source":311,"logo":49,"time":70},69671,"Market voices: Lilly's new obesity drug, Bessent, EQT's robotics move","https://www.msn.com/en-us/money/markets/market-voices-lilly-s-new-obesity-drug-bessent-eqt-s-robotics-move/ar-AA1SaYnT?ocid=finance-verthp-feeds",{"id":313,"title":314,"source":315,"logo":5,"time":70},69670,"Eli Lilly Says Trial of Weight-Loss Drug Retatrutide Yields Encouraging Results","https://www.marketscreener.com/news/eli-lilly-says-trial-of-weight-loss-drug-retatrutide-yields-encouraging-results-ce7d50dbdd8bf025","#8abe3cff","#8abe3c4d",1765665059816]